Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.39 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23901594 | 0.85 | ALDH1A1 (0.42) | MCL1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL22472778 | 0.83 | TSHR (0.39) | NPC1TP53ALOX15RAB9ASMN1; SMN2 | |
| SCHEMBL19449609 | 0.77 | DYRK1A (0.47) | ATRKMT2A | |
| SCHEMBL19438303 | 0.75 | KDM4E (0.46) | ATR | |
| SCHEMBL17741238 | 0.74 | TP53 (0.44) | ATRNPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL19681732 | 0.74 | MKNK1 (0.44) | ATRKMT2A | |
| SCHEMBL19681745 | 0.73 | ADORA2A (0.39) | ATRNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL22472788 | 0.73 | MAPT (0.46) | ATRNPC1TP53RAB9AKMT2A | |
| SCHEMBL23901593 | 0.73 | PTGIR (0.42) | NPC1TP53RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL23901571 | 0.72 | LMNA (0.46) | ATRRAB9ASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309661-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309661-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, GBA2 | ABCB1 1923/4885ABCC1 3838/4885WNT3A 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.